DRUG

Fingolimod

Relapsing multiple sclerosis (FDA 2010)

5 hypotheses across 4 therapeutic domains

CROSS-DOMAIN PATTERN

Same drug, multiple disease domains

Fingolimod appears in hypotheses across 4 disease domains: Epilepsy, Glioblastoma, Inflammatory bowel disease, Rheumatoid arthritis. Shared mediators that recur across at least two of those domains: IL-17A.

Aggregated from the catalog. Biological interpretation of any multi-indication mechanism would require independent validation — this is a structural observation only.

ALL HYPOTHESES

Repurposing candidates for Fingolimod

Epilepsy 2

Mediator Outcome Score Tier Lit. status Trial
HMGB1 epilepsy 0.248 Mid reproduces known none
HMGB1 drug-resistant epilepsy 0.208 Mid partial evidence none

Glioblastoma 1

Mediator Outcome Score Tier Lit. status Trial
mTOR glioblastoma 0.208 Mid reproduces known completed

Inflammatory bowel disease 1

Mediator Outcome Score Tier Lit. status Trial
IL-17A inflammatory bowel disease 0.208 Mid reproduces known none

Rheumatoid arthritis 1

Mediator Outcome Score Tier Lit. status Trial
IL-17A rheumatoid arthritis 0.208 Mid reproduces known none

Clinical trials

137 registered trials for Fingolimod

Source: ClinicalTrials.gov

← All drugs